Due to time constraints, our experiment this year only validated the feasibility of the scheme at the cellular level. If the ultimate goal of medical application is to be achieved, animal and human experiments are also needed to verify the safety and effectiveness in human.
Introducing foreign cells into the human body can easily cause immune rejection reactions, leading to the failure of our project and damage to the patient themselves. Our idea is to extract the patient's own cells, introduce the plasmid we constructed into the cells, and then
reintroduce the cells into the patient's body to greatly reduce immune rejection reactions.
We have had multiple communications and exchanges with relevant companies regarding our blue light bracelet, and have learned that there are currently two most suitable solutions. One is to use non-invasive bracelet to detect blood sugar levels through chemical sensors and the principle of electroosmosis, emitting
blue light when blood sugar exceeds the standard. The second option is to use minimally invasive bracelet, which have more precision compared to the previous solution. This solution causes minimal damage to the patient's skin, but cannot achieve permanent use. In the future, we will design blue light devices that combine precision and practicality to achieve non-invasive and precise blood glucose monitoring.
We will find ways to improve the survival time of engineering cells in the human body, and minimize
the pain and economic burden caused by embedding cells for patients. Meanwhile,
we will investigate how to extend the usage
time of blue light instruments.
Our device needs to consider the cost compared with traditional insulin injection. The life cycle of cells in the device is the most critical factor affecting the service life of the device. The service life of the device directly affects the price of the device. We will get the best conditions to meet the reproduction and death of cells through actual culture and modeling.